Loading
Life sciences · Journal article
Reviews on Recent Clinical Trials · August 29, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review of isatin and isatin-based derivatives as potential antimicrobial agents, focusing on chemical scaffold design, in vitro mechanisms, and structure–activity relationships. The source presents no original clinical efficacy data or randomized trials; it surveys the chemical and mechanistic rationale for isatin derivatives against bacterial, fungal, viral, and mycobacterial pathogens, and notes preclinical or early-stage evaluation of compounds such as TD-1792 and Ro 23-9424. The work is exploratory and does not establish clinical benefit.
Narrative review.
Isatin and its derivatives (Schiff bases, Mannich bases, thiosemicarbazones, azoles, furans, sulfonamides, fluoroquinolones, chalcones, coumarins) are reported to show broad-spectrum antimicrobial activity in vitro. Proposed mechanisms include biofilm suppression, membrane disruption, interference with DNA gyrase and topoisomerase IV, inhibition of cell-wall production, and targeting of vital enzymes FtsZ and CrtM. Isatin-based drugs sunitinib and nintedanib have received clinical approval for cancer treatment; TD-1792 and Ro 23-9424 are noted as undergoing evaluation for infectious diseases.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
This is a narrative review of isatin-based compounds and their putative antimicrobial mechanisms, without new empirical data, clinical trials, or direct evidence of efficacy in humans.
As stated by the source record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract: Novel chemotherapeutic drugs that can fight multidrug-resistant bacteria are desperately needed due to the fast growth of antimicrobial resistance (AMR). As a favoured scaffold in medicinal chemistry, the naturally produced indole derivative isatin (1H-indole-2,3-dione) is found in microorganisms, plants, and the metabolic pathways of mammals, has garnered significant interest. Isatin is a crucial pharmacophore for the creation of broad-spectrum antibacterial medicines because of its adaptable chemical structure and ease of structural alteration at several reactive locations. The therapeutic potential of isatin and its derivatives against bacterial, fungal, viral, and microbacterial diseases is well highlighted in this study. Schiff bases, Mannich bases, thiosemicarbazones, azole, furan, sulfonamide, fluoroquinolone, chalcone, and coumarin conjugates are among the many isatinbased hybrids and analogs that show strong and specific antimicrobial action. According to mechanistic investigations, these compounds function via a variety of mechanisms, including biofilm suppression, membrane disruption, interference with DNA gyrase and topoisomerase IV, inhibition of cell-wall production, and targeting vital enzymes like FtsZ and CrtM. To enhance biological potency and overcome drug resistance, electronic substituents, linker flexibility, and hybridization techniques are crucial, according to structure–activity relationship (SAR) studies. The clinical approval of numerous isatin-based drugs, including sunitinib and nintedanib, for the treatment of cancer, as well as the evaluation of other drugs, like TD-1792 and Ro 23-9424, for the treatment of infectious diseases, demonstrate the translational success of this scaffold. This review focuses on significant advancements, procedures, and potential treatments in isatin-based antimicrobial research.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.